ChiCTR2600123946 版本V1.0 版本创建时间2026/05/04 11:44:45 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123946 

最近更新日期:

Date of Last Refreshed on:

2026-05-04 11:44:07 

注册时间:

Date of Registration:

2026-05-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

利用超声剪切波弹性成像 MyotonPRO 评估亚急性脑卒中偏瘫患者肌肉硬度

Public title:

Assessment of Muscle Stiffness in Subacute Stroke Patients with Hemiplegia Using Ultrasound Shear Wave Elastography and MyotonPRO

注册题目简写:

English Acronym:

研究课题的正式科学名称:

利用超声剪切波弹性成像 MyotonPRO 评估亚急性脑卒中偏瘫患者肌肉硬度

Scientific title:

Assessment of Muscle Stiffness in Subacute Stroke Patients with Hemiplegia Using Ultrasound Shear Wave Elastography and MyotonPRO

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王嘉楠 

研究负责人:

王嘉楠 

Applicant:

Wang Jianan 

Study leader:

Wang Jianan 

申请注册联系人电话:

Applicant telephone:

+86 10 67563322

研究负责人电话:

Study leader's
telephone:

+86 13720007926

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangjianan286@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

wangjianan286@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市丰台区角门北路10号

研究负责人通讯地址:

中国北京市丰台区角门北路10号

Applicant address:

10 Jiaomen North Road, Fengtai District, Beijing, China

Study leader's address:

10 Jiaomen North Road, Fengtai District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国康复研究中心

Applicant's institution:

China Rehabilitation Research Center

研究负责人所在单位:

北京博爱医院

Affiliation of the Leader:

Beijing Bo'ai Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-030-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国康复研究中心医学伦理委员会科研与医疗新技术新项目伦理组

Name of the ethic committee:

Medical Ethics Committee of China Rehabilitation Research Center

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-09 00:00:00

伦理委员会联系人:

何照楠

Contact Name of the ethic committee:

He Zhaonan

伦理委员会联系地址:

中国北京市丰台区角门北路10号

Contact Address of the ethic committee:

10 Jiaomen North Road, Fengtai District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 87020512

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hznhzk@163.com

研究实施负责(组长)单位:

北京博爱医院

Primary sponsor:

Beijing Bo'ai Hospital

研究实施负责(组长)单位地址:

中国北京市丰台区角门北路10号

Primary sponsor's address:

10 Jiaomen North Road, Fengtai District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京博爱医院

具体地址:

中国北京市丰台区角门北路10号

Institution
hospital:

Beijing Bo'ai Hospital

Address:

10 Jiaomen North Road, Fengtai District, Beijing, China

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

脑卒中  

Target disease:

Stroke

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1.明确SWE进行硬度测量的评估者内信度,并确定最小可检测变化值。 2.比较SWE测得的杨氏模量值在健康肌肉、非痉挛肌肉和痉挛肌肉的区别。 3.比较SWE测得的杨氏模量值在偏瘫侧和非偏瘫侧的区别。 4.探讨针对卒中后痉挛患者,SWE测得的杨氏模量值与改良Ashworth量表、改良Tardieu量表分级的相关性。 5.明确SWE测得的杨氏模量值与MyotonPRO测得的的硬度指数在亚急性期脑卒中患者中的相关性。 6.明确MyotonPRO进行硬度测量的评估者内和评估者间信度,并确定最小可检测变化值。 7.比较MyotonPRO测得的肌肉硬度在健康肌肉、非痉挛肌肉和痉挛肌肉的区别。 8.比较MyotonPRO测得的肌肉硬度在偏瘫侧和非偏瘫侧的区别。 9.探讨针对卒中后痉挛患者,MyotonPRO测得的肌肉硬度与改良Ashworth量表、改良Tardieu量表评分的相关性。  

Objectives of Study:

1. Determine the intra-rater reliability of SWE for hardness measurement and establish the minimal detectable change (MDC). 2. Compare Young's modulus values measured by SWE among healthy, non-spastic, and spastic muscles. 3. Compare Young's modulus values measured by SWE between the hemiplegic and non-hemiplegic sides. 4. Investigate the correlation between Young's modulus values measured by SWE and Modified Ashworth Scale (MAS) and Modified Tardieu Scale (MTS) grades in post-stroke spasticity patients. 5. Determine the correlation between Young's modulus values measured by SWE and stiffness index measured by MyotonPRO in subacute stroke patients. 6. Determine the intra-rater and inter-rater reliability of MyotonPRO for hardness measurement and establish the MDC. 7. Compare muscle stiffness measured by MyotonPRO among healthy, non-spastic, and spastic muscles. 8. Compare muscle stiffness measured by MyotonPRO between the hemiplegic and non-hemiplegic sides. 9. Investigate the correlation between muscle stiffness measured by MyotonPRO and MAS and MTS scores in post-stroke spasticity patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄>18岁; 2. 经认证神经科医师确诊为中风,且经认证影像科医师解读的脑部计算机断层扫描(CT)或磁共振成像(MRI)检查证实为缺血性中风或出血性中风; 3. 双侧上下肢被动关节活动范围正常; 4. 首次中风发作,单侧受累; 5. 中风1个月<发病时间<6个月; 6. 上下肢Brunnstrom分期为Ⅲ-Ⅴ期;

Inclusion criteria

1. Age > 18 years; 2. Diagnosed with stroke by a certified neurologist, and confirmed as ischemic stroke or hemorrhagic stroke by brain computed tomography (CT) or magnetic resonance imaging (MRI) reviewed and interpreted by a certified radiologist; 3. First-ever stroke with unilateral neurological involvement; 4. Time since stroke onset: 1 month < duration < 6 months; 5. Normal passive range of motion (PROM) of bilateral upper and lower extremities; 6. Brunnstrom stages Ⅲ–Ⅴ for both upper and lower extremities;

排除标准:

1. 有糖尿病、甲状腺功能亢进或减退病史; 2. 近2年内有严重上下肢外伤; 3. 有其他上下肢周围神经功能缺损病史; 4. 近3个月内使用过抗痉挛药物,包括神经阻滞剂或肉毒杆菌毒素注射; 5. 体重指数(BMI)>30 kg/m^2;

Exclusion criteria:

1. History of diabetes mellitus, hyperthyroidism, or hypothyroidism; 2. Severe trauma to the upper or lower extremities within the past 2 years; 3. History of other peripheral neurological deficits involving the upper and lower extremities, as documented in medical records; 4. Use of antispasmodic medications within the past 3 months, including neurolytic agents or botulinum toxin injections; 5. Body mass index (BMI) > 30 kg/m^2;

研究实施时间:

Study execute time:

From 2026-05-04 00:00:00 To 2027-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-04 00:00:00 To 2027-03-01 00:00:00

干预措施:

Interventions:

组别:

健康对照组

样本量:

20

Group:

Healthy Control Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

卒中后非痉挛组

样本量:

20

Group:

Post-stroke Non-spastic Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

卒中后痉挛组

样本量:

20

Group:

Post-stroke Spastic Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京博爱医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Bo'ai Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

剪切波速度

指标类型:

主要指标

Outcome:

Shear Wave Velocity (SWV)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

杨氏模量

指标类型:

主要指标

Outcome:

Young's Modulus (kPa)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动态硬度

指标类型:

主要指标

Outcome:

Dynamic Stiffness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良 Ashworth 量表 (MAS) 评分

指标类型:

主要指标

Outcome:

Modified Ashworth Scale (MAS) Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良 Tardieu 量表 (MTS) 评分 (R2, R1, R2-R1)

指标类型:

主要指标

Outcome:

Modified Tardieu Scale (MTS) Score (R2, R1, R2-R1)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能性步行量表 (FAC) 评分

指标类型:

主要指标

Outcome:

Functional Ambulation Category (FAC) Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后半年;国家生物信息中心(https://www.cncb.ac.cn/)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Six months after the completion of the research; China National Center for Bioinformation (https://www.cncb.ac.cn/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:数据采集由对分组并不知情的评估人员进行 数据管理:数据存储于加密硬盘,使用编号匿名化,原始测量数据备份于安全硬盘,仅授权人员访问。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data Collection: Data collection was performed by assessors blinded to group assignment. Data Management: Data were stored on an encrypted hard drive and anonymized using identification codes. Raw measurement data were backed up on a secure hard drive, with access restricted to authorized personnel only.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-04 11:44:07